Recent Updates
Recently added Catalysts

PhXA41

Phase 3

Ocular Hypertension | Small molecule | Ophthalmology |Viatris Inc.|Trials Updated: Feb 2, 2021

PhXA41 development status

Highest phase Phase 3
Registered trials 3 across 2 sponsors since Sep 2008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials2
Total Enrollment561

FDA Designations

No designations recorded

PhXA41 clinical trials

PhXA41 · 2 trials · 2 indications

Phase 3 2
NCT00751049A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United KingdomOcular Hypertension
COMPLETED294 Analytics
NCT00751062A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within ScandinaviaOpen Angle Glaucoma
COMPLETED267 Analytics
PHASE3COMPLETED
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
Ocular Hypertension
NCT00751049294
Unlock trial analytics
PHASE3COMPLETED
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
Open Angle Glaucoma
NCT00751062267
Unlock trial analytics

Study Endpoints

Primary Endpoints

to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment
6 mos
to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.
6 mos

Secondary Endpoints

to describe the IOP development throughout the study period and to follow the safety variables in the two treatment groups.
6 mos
to demonstrate the IOP-reducing effect of PhXA41 administered in the morning is equivalent the effect of PhXA41 administered in the evening
6 mos
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PhXA41EXPERIMENTAL -
timololACTIVE_COMPARATOR -

Interventions

NameTypeDescription
timololDRUGOne drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
PhXA41DRUGOne drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension. * Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilatera...

Countries:United KingdomDenmarkFinlandNorwaySweden
Unlock Eligibility Criteria

Competitive Landscape -Ocular Hypertension 11 trials

CompanyTickerTrialsLead PhaseDrugs
SpyGlass Pharma, Inc.SGP5PHASE3Bimatoprost System, BIM-DRS
Amneal Pharmaceuticals, Inc. Class AAMRX1PHASE3Bimatoprost ophthalmic solution
AbbVie, Inc.ABBV1PHASE1AGN-193408
Regeneron Pharmaceuticals, Inc.REGN1PHASE1REGN22530
Glaukos CorpGKOS2 - Travoprost
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Viatris Inc. (VTRS)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with PCompanies A to ZEvery biotech and pharma company we track